GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » 3-Year EBITDA Growth Rate

Histogen (Histogen) 3-Year EBITDA Growth Rate : -27.90% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Histogen 3-Year EBITDA Growth Rate?

Histogen's EBITDA per Share for the three months ended in Sep. 2023 was $-0.90.

During the past 3 years, the average EBITDA Per Share Growth Rate was -27.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Histogen was -27.90% per year. The lowest was -27.90% per year. And the median was -27.90% per year.


Competitive Comparison of Histogen's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Histogen's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Histogen's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Histogen's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Histogen's 3-Year EBITDA Growth Rate falls into.



Histogen 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Histogen  (OTCPK:HSTO) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Histogen 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Histogen's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Histogen (Histogen) Business Description

Traded in Other Exchanges
N/A
Address
10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121
Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
Executives
Joyce Reyes officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe director, officer: See Remarks C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann director C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister director 78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels officer: See Remarks 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson officer: See Remarks 9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson director, 10 percent owner C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton officer: See Remarks C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang director 12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang director C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich officer: See Remarks C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento director C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall officer: EVP, COO & CFO C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127

Histogen (Histogen) Headlines

From GuruFocus

Histogen to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-06-2022

Histogen Announces 1-for-20 Reverse Stock Split

By PurpleRose PurpleRose 07-11-2022

Histogen to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-17-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-01-2022

Histogen Announces 1-for-20 Reverse Stock Split

By GuruFocusNews GuruFocusNews 07-01-2022

Histogen Announces Closing of $4.75 Million Private Placement

By GuruFocusNews GuruFocusNews 03-25-2022

Histogen Announces $4.75 Million Private Placement

By GuruFocusNews GuruFocusNews 03-23-2022